The aesthetic and medical marketing landscape in 2026 looks structurally different than it did 18 months ago. Here's an unfiltered read on what's actually happening — across the practices we work with and the market more broadly.
AI Has Become Baseline Infrastructure
In Q1 2026, deploying AI lead response was a competitive advantage. By Q3 2026, practices without it were losing meaningful market share. By mid-2027, it will be a baseline operational requirement — like having a website.
The competitive edge has moved to how well the AI is trained, how intelligently it routes, and how seamlessly it hands off to human staff. The novelty is gone. Execution quality is the differentiator now.
Practices still debating whether to deploy AI response are not in a strategic conversation. They're in a catch-up conversation.
Meta CPMs Are Up 22% YoY for Medical
Paid media costs for aesthetic brands have risen materially. The practices weathering this best have the strongest conversion infrastructure — because rising CAC is tolerable if your LTV is healthy.
Practices with robust nurture sequences, high consultation show rates, and strong close rates are absorbing the CPM increase without reducing spend. Those without infrastructure are exiting paid media.
The Owned Audience Shift
First-party data is the most important asset a medical practice can build right now. SMS lists, email lists, and GBP followers are platform-independent.
Practices that built these assets over the last two years are seeing lower effective CAC than those dependent entirely on paid platforms. The ones who didn't build are now feeling the cost of that decision in their monthly ad spend.
What's Overrated Right Now
Three things that are getting more attention than they deserve:
- Influencer marketing for aesthetic procedures — high visibility, low pipeline impact
- Short-form video as a primary acquisition channel — engagement metric, not a revenue driver
- AI-generated clinical content without physician oversight — E-E-A-T liability, not an asset
These are engagement plays, not pipeline plays. Too many practices are confusing visibility with revenue. They're not the same metric and they're not interchangeable.